The Experimental Study of Danggui Shaoyao San's Protective Influence on the Dyslipidemia Rats' Vascular Function of Endothelin Cells
|更新时间:2024-01-04
|
The Experimental Study of Danggui Shaoyao San's Protective Influence on the Dyslipidemia Rats' Vascular Function of Endothelin Cells
Chinese Journal of Experimental Traditional Medical FormulaeVol. 13, Issue 2, Pages: 25-28(2007)
作者机构:
作者简介:
基金信息:
DOI:
CLC:
Published:2007
稿件说明:
移动端阅览
YAN Yan-li1, JI Mei2, SONG Xiao-yu3, et al. The Experimental Study of Danggui Shaoyao San's Protective Influence on the Dyslipidemia Rats' Vascular Function of Endothelin Cells[J]. Chinese journal of experimental traditional medical formulae, 2007, 13(2): 25-28.
DOI:
YAN Yan-li1, JI Mei2, SONG Xiao-yu3, et al. The Experimental Study of Danggui Shaoyao San's Protective Influence on the Dyslipidemia Rats' Vascular Function of Endothelin Cells[J]. Chinese journal of experimental traditional medical formulae, 2007, 13(2): 25-28.DOI:
The Experimental Study of Danggui Shaoyao San's Protective Influence on the Dyslipidemia Rats' Vascular Function of Endothelin Cells
Objective:To observe the effect of Danggui Shaoyao San(DSS) on lipid's peroxidation and the expression of VCAM-1mRNA in dyslipidemia rats.Methods:Hyperlipemia of rat model was duplicated by feeding high lipid fodder
at the same time
the rats were treated with DSS and positive control medicine.Eight weeks later
blood lipids level as well as the content of ox-LDL、MDA and SOD were detected by RIA kit.The expression of the VCAM-1mRNA was detected by RT-PCR.Results:The TC、TG、LDL-C、ox-LDL and MDA in DSS group and the positive control group were decreased while the HDL-C and SOD were increased
compared with the model group(P<0.01 or P<0.05).The result of RT-PCR showed that DSS and positive control group could inhibit the VCAM-1mRNA' expression in the rat aorta.Conclusion:DSS can inhibit lipid's peroxidation damage and decrease the expression of VCAM-1mRNA in rats.The results indicated that DSS could protect the VEC's function.
Evaluation of GRADE Clinical Research Evidence of Chinese Patent Medicine Combined with Western Medicine in Treatment of Hypertension with Dyslipidemia
Notoginseng Radix et Rhizoma Powder Treats Dyslipidemia via PI3K/Akt Signaling Pathway
Oral Chinese Patent Medicines for Hyperlipidemia: A Scoping Review of Clinical Evidence
Advances in Mechanism of Traditional Chinese Medicines and Its Active Ingredients Treating Dyslipidemia
Clinical Efficacy of Zhibitai Capsule in Treating Patients of Dyslipidemia with Phlegm-stasis Binding Pattern
Related Author
HAN Xuejie
WANG Jiaheng
LI Yukun
CUI Liangyu
ZHENG Yilan
ZHAO Zhiwei
REN Cong
JING Tianyue
Related Institution
Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences
Shaanxi University of Chinese Medicine
Dongzhimen Hospital, Beijing University of Chinese Medicine
Henan University of Chinese Medicine
Third Affiliated Hospital of Henan University of Chinese Medicine